2. Immunology/Inflammation Apoptosis
  3. IFNAR TNF Receptor Tim3
  4. 184475-35-2

184475-35-2

Gefitinib Chemical Structure

184475-35-2

Chemical Structure

  • Gefitinib
  • Synonym(s): ZD1839
  • CAS No: 184475-35-2
    Formula: C22H24ClFN4O3
    Molecular Weight: 446.90
  • IUPAC Name: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
  • InChIKey: XGALLCVXEZPNRQ-UHFFFAOYSA-N
  • SMILES: ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F

Biological Activity: Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer [1][2][5].

Cat. No. Product Name Purity Description
HY-N14060 Halymecin C Halymecin C is found in the strain of Fusarium sp. FE-71-1.

References

[1]. Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54. [Content Brief]
[2]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93(8):915-23. [Content Brief]
[5]. Marie P Piechocki, et al. Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Int J Cancer. 2008 Apr 15;122(8):1722-9. [Content Brief]

Keywords:

Gefitinib (Standard)Gefitinib (GMP)GefitinibGefitinib-d8Gefitinib-d3Gefitinib-d6